Press Release
January 30, 2024

AQEMIA Extends Series A to €60 Million

The Goodwin Technology and Life Sciences team advised AQEMIA on its €30 million extension financing round bringing its Series A up to €60 million.

AQEMIA leverages its unique Deep Physics-powered AI to uncover breakthrough drug candidates at scale.

This round was led by Wendel Growth and included Bpifrance through its Large Venture Fund, Eurazeo and Elaia.

This funding will allow AQEMIA to accelerate the development of its proprietary pipeline of drug discovery projects and assets, with the latter already counting several projects being tested in animals, mostly in the fields of oncology and immuno-oncology.

The Goodwin team was led by Xavier Leroux and included Augustin Piqueras on corporate aspects, and Marie Fillon on IP aspects.